×

Novo Nordisk A/S: Saxenda(R) for the treatment of obesity receives positive 14-1 vote in favour of approval from FDA Advisory Committee

BAGSVAERD, Denmark, Sept. 11, 2014 (GLOBE NEWSWIRE) -- Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the United States Food and Drug Administration (FDA) has completed its meeting regarding the New Drug Application (NDA) for Saxenda®, the intended brand name for liraglutide 3 mg, a once-daily human GLP-1 analogue for the treatment of obesity.

For further information

Media:
Katrine Sperling +45 3079 6718 krsp@novonordisk.com
Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com
Investors:
Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com
Jannick Lindegaard Denholt +45 3079 8519 jlis@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com
Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com

Company announcement No 56 / 2014

Company announcement No 56 / 2014 http://hugin.info/2013/R/1855498/649145.pdf

HUG#1855498

Source:Novo Nordisk A/S